- Home
- OPK vs PHVS Comparison
OPK vs PHVS Comparison
Compare OPK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- PHVS
- Stock Information
- Founded
- OPK 2007
- PHVS 2015
- Country
- OPK United States
- PHVS Switzerland
- Employees
- OPK N/A
- PHVS N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- PHVS Health Care
- Exchange
- OPK Nasdaq
- PHVS Nasdaq
- Market Cap
- OPK 1.0B
- PHVS 1.3B
- IPO Year
- OPK 1995
- PHVS 2021
- Fundamental
- Price
- OPK $1.38
- PHVS $23.38
- Analyst Decision
- OPK Buy
- PHVS Strong Buy
- Analyst Count
- OPK 4
- PHVS 5
- Target Price
- OPK $2.75
- PHVS $35.60
- AVG Volume (30 Days)
- OPK 1.9M
- PHVS 123.8K
- Earning Date
- OPK 11-06-2025
- PHVS 11-12-2025
- Dividend Yield
- OPK N/A
- PHVS N/A
- EPS Growth
- OPK N/A
- PHVS N/A
- EPS
- OPK N/A
- PHVS N/A
- Revenue
- OPK $664,029,000.00
- PHVS N/A
- Revenue This Year
- OPK N/A
- PHVS N/A
- Revenue Next Year
- OPK $0.84
- PHVS N/A
- P/E Ratio
- OPK N/A
- PHVS N/A
- Revenue Growth
- OPK N/A
- PHVS N/A
- 52 Week Low
- OPK $1.11
- PHVS $11.51
- 52 Week High
- OPK $2.04
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- OPK 50.29
- PHVS 55.19
- Support Level
- OPK $1.34
- PHVS $23.20
- Resistance Level
- OPK $1.44
- PHVS $24.83
- Average True Range (ATR)
- OPK 0.04
- PHVS 1.34
- MACD
- OPK -0.00
- PHVS -0.02
- Stochastic Oscillator
- OPK 40.00
- PHVS 58.45
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.